Simvastatin Tablet, Film Coated
Product Images NDC 50090-6459

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 50090-6459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

Footnote For Table 3 (Footnote For Table 3)
This text discusses the results of a chemical assay related to CYP3A4 inhibitors, such as ketoconazole and erythromycin, and their effect on simvastatin acid. It also mentions the potential impact of double and single-strength grapefruit juice on simvastatin pharmacokinetics, but notes that the specific effect of grapefruit juice has not been studied. Results with propranolol are not included.*
FDA Label Image

Label Image (Lbl500906459)

Label Image (Lbl500906459)
This is a product description for a medication called ShvasTATIN, which comes in a package with 30 tablets. The product code is 6i50-0 and the brand may be represented by the letters SHG. The first line of text has a non-English character and may not be useful for understanding the description.*
FDA Label Image

Figure 9 (Simvastatin 10)

Figure 9 (Simvastatin 10)
FDA Label Image

Table2 (Simvastatin 2)

Table2 (Simvastatin 2)
The text describes data in a table that shows adverse reactions reported by patients using Simvastatin and are greater than those who used Placebo. The table includes the number of patients in each group (N=2223), and the percentage of patients that reported adverse reactions, grouped by body system or disorder. Some of the most commonly reported adverse reactions for Simvastatin users were abdominal pain, atrial fibrillation, eczema, and myalgia.*
FDA Label Image

Structure (Simvastatin 3)

Structure (Simvastatin 3)
FDA Label Image

Table 3 (Simvastatin 4)

Table 3 (Simvastatin 4)
FDA Label Image

Table 4 (Simvastatin 5)

Table 4 (Simvastatin 5)
FDA Label Image

Figure 5 (Simvastatin 6)

Figure 5 (Simvastatin 6)
FDA Label Image

Figure 6 (Simvastatin 7)

Figure 6 (Simvastatin 7)
FDA Label Image

Figure 7 (Simvastatin 8)

Figure 7 (Simvastatin 8)
FDA Label Image

Figure 8 (Simvastatin 9)

Figure 8 (Simvastatin 9)
FDA Label Image

Table 1 (Table1)

Table 1 (Table1)
This is a drug interaction table listing drugs associated with increased risk of myopathy/rhabdomyolysis. It includes prescribing recommendations such as avoiding the use of certain drugs or adjusting dosage for others, particularly in combination. The table includes several specific drugs and drug classes. Not-readable text is present at the end.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.